AcelRx Pharmaceuticals is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. DSUVIA® (known as DZUVEO™ in Europe) and Zalviso® are both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, for use in medically supervised settings. Co.'s portfolio includes ARX-02 Higher Strength Sufentanil Sublingual Tablet for cancer breakthrough pain in opioid-tolerant patients; and ARX-03 Combination Sufentanil/Triazolam Sublingual Tablet for mild sedation and pain relief during painful procedures in a physician's office. We show 44 historical shares outstanding datapoints in our ACRX shares outstanding history coverage, used to compute ACRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ACRX market cap history over the course of time is important for investors
interested in comparing ACRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ACRX versus a peer is one thing; comparing
ACRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ACRX can fluctuate over the course of history.
With this page we aim to empower investors researching ACRX by allowing them to research the ACRX market cap history. |
Video: The Importance of Market Cap
